

# CITATION REPORT

List of articles citing

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

DOI: 10.1016/s0002-9149(97)00965-x

American Journal of Cardiology, 1998, 81, 582-7.

**Source:** <https://exaly.com/paper-pdf/28950802/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
930	Statins and fibrinogen. <b>1998</b> , 351, 1430-1; author reply 1431-2		5
929	The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines. <b>1998</b> , 14 Suppl 3, 19-28		13
928	Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols. <b>1998</b> , 14 Suppl 3, 29-38		5
927	Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease. <b>1998</b> , 14, 217-36		8
926	Effect of Atorvastatin versus Simvastatin on Lipid Profile and Plasma Fibrinogen in Patients with Hypercholesterolaemia: A Pilot, Randomised, Double-Blind, Dose-Titrating Study. <b>1998</b> , 16, 219-27		12
925	Management of Dyslipidaemias. <b>1998</b> , 3, 293-311		2
924	Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. <b>1998</b> , 32, 1030-43		36
923	Detecting and correcting hyperlipidemia. <b>1998</b> , 33, 83-90, 95-9; discussion 99-100, 102		
922	Maximizing the cost-effectiveness of lipid-lowering therapy. <b>1998</b> , 158, 1977-89		54
921	Efficacy and Safety of Atorvastatin in Patients with Hypercholesterolemia. <b>1999</b> , 29, 928		4
920	Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. <b>1999</b> , 281, 137-44		177
919	Natural statins and stroke risk. <b>1999</b> , 99, 185-8		100
918	Chronic creatine kinase elevation not associated with HMG-CoA reductase inhibitor treatment. <b>1999</b> , 33, 163-6		3
917	Prognostic and therapeutic significance of low levels of high-density lipoprotein cholesterol: current perspectives. <b>1999</b> , 159, 1038-40		7
916	The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs. <b>1999</b> , 140, 5293-302		46
915	Dyslipidaemia and cardiovascular risk in diabetes. <b>1999</b> , 1, 189-98		24
914	Type 2 diabetes towards the new millennium--the relative importance of glycaemic versus lipid control. <b>1999</b> , 29, 249-53		

913	Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. <b>1999</b> , 13 Suppl 1, S3-10; discussion S33-4		13
912	Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits. <b>1999</b> , 127, 1479-85		40
911	Lowering effects of four different statins on serum triglyceride level. <b>1999</b> , 55, 499-502		32
910	[Therapy with CSE inhibitors--more than lipid lowering?]. <b>1999</b> , 24, 42-50		1
909	Combination drug therapy for dyslipidemia. <b>1999</b> , 1, 44-9		8
908	The outcome of very low dosages of simvastatin in patients with hypercholesterolemia. <b>1999</b> , 19, 399-403		1
907	Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. <i>American Journal of Cardiology</i> , <b>1999</b> , 83, 1476-7, A7	3	106
906	Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). <i>American Journal of Cardiology</i> , <b>1999</b> , 84, 7-13	3	34
905	Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. <b>1999</b> , 282, 771-8		217
904	Efficacy and safety of atorvastatin and pravastatin in patients with hypercholesterolemia. <b>1999</b> , 10, 33-39		5
903	The essence of effective treatment and compliance is simplicity. <b>1999</b> , 12, 105S-110S		14
902	Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. <b>1999</b> , 69, 237-44		48
901	[Opposable medical references of the ANDEM concerning hyperlipidemia and its treatment]. <b>1999</b> , 20, 341-6		
900	A population-based treat-to-target pharmaco-economic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. <b>1999</b> , 21, 536-62		24
899	A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study. <b>1999</b> , 21, 1788-96		8
898	Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. <b>1999</b> , 146, 167-74		50
897	High risk strategies for atherosclerosis. <b>1999</b> , 286, 31-45		19
896	Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. <b>1999</b> , 65, 1329-37		85

895	Fluvastatin: a review of its use in lipid disorders. <b>1999</b> , 57, 583-606		50
894	Cost of Treating to a Modified European Atherosclerosis Society LDL-C Target. <b>1999</b> , 17, 185-193		17
893	The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. <b>1999</b> , 143, 41-54		81
892	More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia. <b>1999</b> , 143, 455-7		17
891	The future of best practice. <b>1999</b> , 143 Suppl 1, S17-21		34
890	Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. <b>1999</b> , 33, 1176-9		72
889	Effects of statins on carotid disease and stroke. <b>1999</b> , 10, 535-41		5
888	Forecasting patient outcomes in the management of hyperlipidemia. <b>1999</b> , 159, 569-75		3
887	Statins: where are we now?. <b>2000</b> , 61, 789-92		1
886	Effects of Fluvastatin and Bezafibrate Combination on Plasma Fibrinogen, t-plasminogen Activator Inhibitor and C Reactive Protein Levels in Coronary Artery Disease Patients with Mixed Hyperlipidaemia (FACT Study). <b>2000</b> , 83, 549-553		49
885	Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?. <b>2000</b> , 11, 627-37		76
884	Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. <b>2000</b> , 14, 125-31		39
883	Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis. <b>2000</b> , 4, 244-8		5
882	Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. <b>2000</b> , 2, 355-62		38
881	Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study. <b>2000</b> , 20, 819-22		17
880	Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. <i>American Journal of Cardiology</i> , <b>2000</b> , 86, 250-2	3	18
879	Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. <i>American Journal of Cardiology</i> , <b>2000</b> , 86, 221-3	3	60
878	Cholesterol lowering in atherosclerosis. <i>American Journal of Cardiology</i> , <b>2000</b> , 86, 29H-32H	3	15

877	Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. <i>American Journal of Cardiology</i> , <b>2000</b> , 86, 1123-7	3	15
876	Statins, high-density lipoprotein, and the low-density lipoprotein/high-density lipoprotein ratio. <i>American Journal of Cardiology</i> , <b>2000</b> , 86, 593-4	3	5
875	Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. <i>American Journal of Cardiology</i> , <b>2000</b> , 86, 1250-3, A6	3	24
874	Divergent approaches to the treatment of dyslipidemia with low levels of high-density lipoprotein cholesterol. <i>American Journal of Cardiology</i> , <b>2000</b> , 86, 57L-61L	3	47
873	Twenty questions on atherosclerosis. <b>2000</b> , 13, 139-43		7
872	PANDORA - Survey of Brazilian cardiologists about cholesterol reduction. <b>2000</b> , 75, 289-302		2
871	Retrospective Evaluation of the Lipid-Lowering Effects of Atorvastatin. <b>2000</b> , 16, 89-91		
870	Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. <b>2000</b> , 57, 461-4		31
869	Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic. <b>2000</b> , 57, 1703-8		9
868	Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. <b>2000</b> , 20, 189-97		204
867	Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. <b>2000</b> , 15, 684-8		28
866	Atorvastatin improves postprandial lipoprotein metabolism in normolipidemic subjects. <b>2000</b> , 85, 4224-30		50
865	HDL-cholesterol and the Treatment of Coronary Heart Disease: Contrasting Effects of Atorvastatin and Simvastatin. <b>2000</b> , 16, 139-146		48
864	The nature of the statins. <b>2000</b> , 101, E89		
863	Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. <b>2000</b> , 5, 27-32		26
862	Statins: effective antiatherosclerotic therapy. <b>2000</b> , 139, 577-83		131
861	Use of cholesterol-lowering medications in the United States from 1991 to 1997. <b>2000</b> , 108, 496-9		50
860	The role of small, dense low density lipoprotein (LDL): a new look. <b>2000</b> , 74 Suppl 1, S17-22		96

859	Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. <b>2000</b> , 19, 529-37	79
858	Atorvastatin and the plasma activities of lipoprotein lipase, hepatic lipase and lecithin:cholesterol acyltransferase in patients with mixed hyperlipidemia. <b>2000</b> , 11, 33-38	3
857	A multicenter, open-label, randomized study comparing the efficacy of atorvastatin versus usual care in reducing refractory hypercholesterolemia in high-risk patients to target levels. <b>2000</b> , 61, 175-190	2
856	Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. <b>2000</b> , 355, 2185-8	333
855	Management of Dyslipidaemias. <b>2000</b> , 7, 83-109	3
854	Current perspectives on statins. <b>2000</b> , 101, 207-13	958
853	The Effect of Atorvastatin on Serum Lipids, Lipoprotein(a) and Plasma Fibrinogen Levels in Primary Dyslipidaemia [A Pilot Study Involving Serial Sampling. <b>2000</b> , 16, 269-275	10
852	Pharmacotherapy of hypercholesterolaemia: statins in clinical practice. <b>2000</b> , 1, 683-95	23
851	Management of hypercholesterolemia. <b>2000</b> , 84, 23-42	45
850	Diabetic dyslipidaemia: current treatment recommendations. <b>2000</b> , 59, 1101-11	33
849	Lipid-lowering treatment in coronary artery disease: how low should cholesterol go?. <b>2000</b> , 59, 1127-35	5
848	Current, new and future treatments in dyslipidaemia and atherosclerosis. <b>2000</b> , 60, 55-93	53
847	A Working-Day Evaluation of Dyslipidaemia in a Spanish Population (JADE Study). <b>2000</b> , 19, 131-142	6
846	Additional Efficacy of Milligram-Equivalent Doses of Atorvastatin over Simvastatin. <b>2000</b> , 19, 327-334	5
845	Rationale, Design and Baseline Characteristics of a Clinical Trial Comparing the Effects of Robust vs Conventional Cholesterol Lowering and Intima Media Thickness in Patients with Familial Hypercholesterolaemia : The Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) Study. <b>2000</b> , 20, 67-79	24
844	The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy. <b>2000</b> , 153, 89-98	23
843	Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes. <b>2000</b> , 153, 283-94	47
842	More on atorvastatin and fibrinogen. <b>2000</b> , 151, 591-2	5

841	Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. <b>2000</b> , 149, 123-9	31
840	Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. <b>2000</b> , 151, 493-9	47
839	Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice. <b>2000</b> , 149, 199-205	19
838	Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study. <b>2000</b> , 152, 489-96	22
837	Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. <b>2001</b> , 61, 197-206	73
836	Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. <b>2001</b> , 61, 1835-81	111
835	Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program. <b>2001</b> , 21, 1130-9	20
834	Effects of initial and long-term lipid-lowering therapy on vascular wall characteristics. <b>2001</b> , 154, 155-61	20
833	Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. <b>2001</b> , 157, 107-15	42
832	Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment. <b>2001</b> , 159, 513-9	36
831	Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial. <b>2001</b> , 35, 86-91	32
830	Atorvastatin Plus Pravastatin for the Treatment of Heterozygous Familial Hypercholesterolaemia -A Pilot Study. <b>2001</b> , 17, 267-272	3
829	How well tolerated are lipid-lowering drugs?. <b>2001</b> , 18, 665-83	21
828	Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. <b>2001</b> , 110, 352-60	166
827	Statins and cancer: a case of meta-uncertainty. <b>2001</b> , 110, 738-40	12
826	Clinically relevant differences between the statins: implications for therapeutic selection. <b>2001</b> , 111, 390-400	154
825	The influence of simvastatin on lipase and cholesterol esterase activity in the serum of men with coronary heart disease. <b>2001</b> , 43, 359-62	11
824	Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)--a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness. <b>2001</b> , 141, 342-7	17

823	Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia. <b>2001</b> , 23, 851-7	16
822	High-density lipoprotein cholesterol: an updated view. <b>2001</b> , 1, 109-12	5
821	Comparison of two regimens of policosanol administered at 20 mg/d in patients with type II hypercholesterolemia: a randomized, double-blind, placebo-controlled study. <b>2001</b> , 62, 194-208	8
820	Effects of atorvastatin 10 mg and simvastatin 20 mg on serum triglyceride levels in patients with hypercholesterolemia. <b>2001</b> , 62, 408-415	4
819	Eficacia y seguridad de la atorvastatina en la práctica médica habitual en España (estudio Zar). <b>2001</b> , 13, 19-25	
818	Evaluación farmacoeconómica de la reducción de colesterol con inhibidores de la HMG-CoA reductasa (estatinas) en la hipercolesterolemia. <b>2001</b> , 13, 241-253	3
817	[Cost-effectiveness of atorvastatin against simvastatin as hypolipemic treatment in hypercholesterolemic patients in primary care]. <b>2001</b> , 27, 18-24	5
816	MANAGEMENT OF HYPERCHOLESTEROLEMIA. <b>2001</b> , 19, 295-310	1
815	Augmenting reference pricing of pharmaceuticals in New Zealand with strategic cross-product agreements. <b>2001</b> , 19, 365-77	8
814	The HMG-CoA reductase inhibitors [new safety concerns?]. <b>2001</b> , 17, 11-15	
813	Atorvastatin. <b>2001</b> , 2, 819-30	19
812	Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC. <b>2001</b> , 6, 137-45	28
811	A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol. <b>2001</b> , 42, 725-38	19
810	Normocholesterolaemic dyslipidaemia: is there a role for fibrates?. <b>2001</b> , 174, 610; author reply 611	
809	. <b>2001</b> , 8, 383-390	115
808	Lipid disorders in patients with type 2 diabetes. Meeting the challenges of early, aggressive treatment. <b>2001</b> , 110, 111-4, 117-8, 121-3	6
807	[Atorvastatin (Lipitor): a review of its pharmacological and clinical profile]. <b>2001</b> , 117, 65-76	8
806	Treating lipids in cardiovascular disease: new directions. <b>2001</b> , 3, B27-B31	1



805	Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy. <b>2001</b> , 11, 368-383		3
804	The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial. <b>2001</b> , 56, 109-14		7
803	Similar Effects of Atorvastatin, Simvastatin and Pravastatin on Thrombogenic and Inflammatory Parameters in Patients with Hypercholesterolemia. <b>2001</b> , 85, 47-51		94
802	The UKPDS: implications for the dyslipidaemic patient. <b>2001</b> , 38 Suppl 1, S9-14		12
801	Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis. <b>2001</b> , 229, 75-86		38
800	Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. <b>2001</b> , 15, 211-8		51
799	Effect of atorvastatin 15 mg/week on serum lipids in patients with hypercholesterolemia. <i>American Journal of Cardiology</i> , <b>2001</b> , 87, 341-2, A9	3	
798	Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. <i>American Journal of Cardiology</i> , <b>2001</b> , 87, 554-9	3	56
797	Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin. <i>American Journal of Cardiology</i> , <b>2001</b> , 87, 33B-36B	3	26
796	Tachyphylaxis and statin drugs. <i>American Journal of Cardiology</i> , <b>2001</b> , 87, 674	3	1
795	Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. <i>American Journal of Cardiology</i> , <b>2001</b> , 87, 1174-80; A4	3	45
794	Tachyphylaxis in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. <i>American Journal of Cardiology</i> , <b>2001</b> , 87, 1032-4	3	1
793	Reply. <i>American Journal of Cardiology</i> , <b>2001</b> , 87, 1032-1034	3	1
792	Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. <i>American Journal of Cardiology</i> , <b>2001</b> , 88, 504-8	3	168
791	Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. <i>American Journal of Cardiology</i> , <b>2001</b> , 88, 635-9	3	11
790	Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention. <i>American Journal of Cardiology</i> , <b>2001</b> , 88, 33J-37J	3	21
789	Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. <b>2001</b> , 62, 1545-55		73
788	Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. <b>2001</b> , 431, 345-52		25

787	Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins. <b>2001</b> , 15, 211-26	23
786	Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease. <b>2001</b> , 21, 410-5	23
785	Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. <b>2001</b> , 103, 1933-5	605
784	Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. <b>2001</b> , 8, 383-90	50
783	Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. <b>2001</b> , 103, 2213-8	91
782	The Friedewald formula underestimates LDL cholesterol at low concentrations. <b>2001</b> , 39, 426-31	87
781	Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. <b>2001</b> , 21, 2026-31	54
780	Elevated baseline triglyceride levels modulate effects of HMGCoA reductase inhibitors on plasma lipoproteins. <b>2001</b> , 6, 47-56	9
779	Statin therapy--what now?. <b>2001</b> , 39, 17-21	10
778	The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. <b>2001</b> , 24, 1335-41	113
777	Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. <b>2002</b> , 42, 835-45	64
776	Lipids and diabetes mellitus: a review of therapeutic options. <b>2002</b> , 18 Suppl 1, s58-74	3
775	Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. <b>2002</b> , 9, 33-9	13
774	Influence of socioeconomic status on drug selection for the elderly in Canada. <b>2002</b> , 36, 804-8	37
773	Adherence with statin therapy in elderly patients with and without acute coronary syndromes. <b>2002</b> , 288, 462-7	768
772	Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia. <b>2002</b> , 87, 4991-5000	33
771	Antioxidant vitamins and lipid therapy: end of a long romance?. <b>2002</b> , 22, 1535-46	64
770	Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. <b>2002</b> , 25, 1211-6	86

769	Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. <b>2002</b> , 22, 1524-34	123
768	Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit. <b>2002</b> , 106, 2955-60	34
767	Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors. <b>2002</b> , 36, 1907-17	25
766	Causal structures for evaluating statin class effects. <b>2002</b> , 36, 1961-5	1
765	High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes. <b>2002</b> , 13, 315-22	9
764	. <b>2002</b> , 9, 33-39	27
763	Beyond LDL-C--the importance of raising HDL-C. <b>2002</b> , 18, 36-44	33
762	High-density lipoprotein cholesterol and the role of statins. <b>2002</b> , 66, 1037-44	26
761	Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. <b>2002</b> , 25, 1198-202	226
760	Rosuvastatin for the treatment of patients with hypercholesterolemia. <b>2002</b> , 36, 93-101	22
759	A look to the future: new treatment guidelines and a perspective on statins. <b>2002</b> , 112 Suppl 8A, 34S-41S	8
758	The importance of lipid evaluation and management in the prevention and treatment of acute myocardial infarction. <b>2002</b> , 5, 131-7	1
757	ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. <b>2002</b> , 106, 2055-60	470
756	Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. <b>2002</b> , 39, 1020-5	259
755	Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. <b>2002</b> , 162, 23-31	65
754	Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia. <b>2002</b> , 162, 163-70	24
753	Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. <b>2002</b> , 162, 245-51	37
752	A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. <b>2002</b> , 162, 373-9	98

751	Pravastatin sodium, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases serum total cholesterol in Japanese White rabbits by two different mechanisms. <b>2002</b> , 162, 299-306	11
750	Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. <b>2002</b> , 163, 59-68	37
749	Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. <b>2002</b> , 163, 287-96	86
748	Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. <b>2002</b> , 164, 361-9	105
747	The discovery and development of atorvastatin, a potent novel hypolipidemic agent. <b>2002</b> , 40, 1-22	159
746	Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. <b>2002</b> , 62, 2333-47	59
745	Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs. <b>2002</b> , 359, 2271-3	52
744	A randomized, double-blind, placebo-controlled study of the efficacy and tolerability of policosanol in adolescents with type II hypercholesterolemia. <b>2002</b> , 63, 286-303	10
743	Efficacy and therapeutic potential of plant sterols. <b>2002</b> , 3, 11-5	21
742	Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. <b>2002</b> , 144, 1044-51	145
741	Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. <b>2002</b> , 144, 1036-43	129
740	Safety and efficacy of atorvastatin in heart transplant recipients. <b>2002</b> , 21, 204-10	27
739	Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats. <b>2002</b> , 1580, 161-70	17
738	Effectiveness of low doses of simvastatin versus atorvastatin: resolving conflicting evidence. <b>2002</b> , 24, 325-8	
737	The authors reply:. <b>2002</b> , 24, 326-328	
736	Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. <b>2002</b> , 84, 53-7	41
735	Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in Statin studies with familial hypercholesterolemia (ExPRESS FH). <b>2002</b> , 164, 347-54	15
734	Isotopomer spectral analysis of intermediates of cholesterol synthesis in human subjects and hepatic cells. <b>2002</b> , 282, E1222-30	16

733	Update on the management of dyslipidemia. <b>2002</b> , 59, 1615-25		2
732	Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors. <b>2002</b> , 59, 1173-9; quiz 1180-2		7
731	Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study. <b>2002</b> , 9, 48-56		19
730	Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. <b>2002</b> , 22, 738-47		38
729	Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor. <b>2002</b> , 455, 161-7		16
728	Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. <i>American Journal of Cardiology</i> , <b>2002</b> , 89, 268-75	3	199
727	Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. <i>American Journal of Cardiology</i> , <b>2002</b> , 89, 667-71	3	52
726	Combination therapy for dyslipidemia: safety and regulatory considerations. <i>American Journal of Cardiology</i> , <b>2002</b> , 90, 50K-60K	3	85
725	Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. <i>American Journal of Cardiology</i> , <b>2002</b> , 90, 30K-43K	3	129
724	Pharmaceutical initiatives to combat atherosclerosis—What to do with the good, the bad, and the ugly lipoproteins. <b>2002</b> , 15, 204-215		2
723	High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. <b>2002</b> , 37, 445-54		43
722	Lipoprotein changes with statins. <b>2002</b> , 4, 14-8		7
721	Statins: the new aspirin?. <b>2002</b> , 59, 1771-86		72
720	[Statins and cerebrovascular events]. <b>2002</b> , 27, 765-71		1
719	Answering the unanswered questions: ongoing trials of statins and antihypertensives in type 2 diabetes. <b>2002</b> , 39 Suppl 2, S46-51		
718	A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. <b>2002</b> , 61, 1469-74		51
717	Time-dependent effect of statins on platelet function in hypercholesterolaemia. <b>2002</b> , 32, 901-8		74
716	Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. <b>2002</b> , 19, 201-11		81

715	The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia. <b>2002</b> , 58, 501-6		38
714	HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins. <b>2003</b> , 17, 53-62		22
713	Cholesterol absorption inhibitors: defining new options in lipid management. <b>2003</b> , 26, 259-64		15
712	Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. <b>2003</b> , 26, 509-14		13
711	Comparing HMG-CoA reductase inhibitors. <b>2003</b> , 26, 115-20		14
710	Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. <b>2003</b> , 18, 113-24		43
709	Achtergronden van de behandelingsadviezen bij hypercholesterolemiedyslipidemie. <b>2003</b> , 19, 83-89		
708	Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects. <b>2003</b> , 3, 45-53		16
707	Long-term Efficacy and Safety of Atorvastatin in Dyslipidemic Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. <b>2003</b> , 5, 78-83		
706	Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. <b>2003</b> , 141, 131-7		95
705	Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 1287-93	3	90
704	A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 1447-51	3	55
703	Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. <i>American Journal of Cardiology</i> , <b>2003</b> , 91, 3C-10C; discussion 10C	3	110
702	Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 152-60	3	974
701	Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 670-6	3	143
700	Statin therapy for the treatment of diabetic dyslipidemia. <b>2003</b> , 19, 280-7		11
699	Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modeling. <b>2003</b> , 74, 1-8		23
698	[Non-lipid effects of statins: myth or fact?]. <b>2003</b> , 153, 244-9		1

697	Management of lipids in patients with diabetes. <b>2003</b> , 5 Suppl 1, S3-9	1
696	Panax notoginseng (Burk.) effects on fibrinogen and lipid plasma level in rats fed on a high-fat diet. <b>2003</b> , 17, 174-8	76
695	YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents. <b>2003</b> , 139, 140-6	18
694	Inhibici3n de la absorci3n intestinal del colesterol: nueva diana terap3utica en la reducci3n de la colesterolemia. <b>2003</b> , 15, 261-275	1
693	Management of dyslipidemias in the age of statins. <b>2003</b> , 30, 641-69	2
692	Eficiencia de los principales f3rmacos utilizados como tratamiento de la hipercolesterolemia en atenci3n primaria. <b>2003</b> , 15, 239-247	
691	Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. <b>2003</b> , 78, 965-78	297
690	Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: relevance to the in vivo metabolism of triglyceride-rich lipoproteins. <b>2003</b> , 166, 311-21	24
689	Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia. <b>2003</b> , 167, 97-104	12
688	The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. <b>2003</b> , 167, 243-55	76
687	High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. <b>2003</b> , 168, 195-211	169
686	Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy. <b>2003</b> , 168, 289-95	33
685	Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment. <b>2003</b> , 63, 1907-45	52
684	Atorvastatin versus Bezafibrate in Mixed Hyperlipidaemia : Randomised Clinical Trial of Efficacy and Safety (the ATOMIX Study). <b>2003</b> , 23, 153-65	0
683	Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. <b>2003</b> , 23, 639-50	24
682	Role of lipid and lipoprotein profiles in risk assessment and therapy. <b>2003</b> , 146, 227-33	50
681	Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. <b>2003</b> , 145, 1036-45	18
680	Statin use is associated with enhanced collateralization of severely diseased coronary arteries. <b>2003</b> , 146, 876-81	47

679	Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). <b>2003</b> , 146, 862-9	59
678	Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. <b>2003</b> , 114, 485-94	40
677	Bridging the treatment gap: improving compliance with lipid-modifying agents and therapeutic lifestyle changes. <b>2003</b> , 6, 204-11	16
676	Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. <b>2003</b> , 52, 1279-86	27
675	Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: a twenty-four-week, open-label, dose-increasing study. <b>2003</b> , 64, 236-47	5
674	A six-month, multicenter, open-label, noncomparative, prospective, observational study of the efficacy and tolerability of atorvastatin in the primary care setting (estudio del control de las hiperlipidemias en atención primaria): the cheap study. <b>2003</b> , 64, 338-54	
673	Effects of stable fish oil and simvastatin on plasma lipoproteins in patients with hyperlipidemia. <b>2003</b> , 23, 1027-1034	5
672	An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. <b>2003</b> , 25, 1186-99	8
671	A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d. <b>2003</b> , 25, 2738-53	16
670	A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study. <b>2003</b> , 25, 119-38	23
669	Squalene epoxidase as hypocholesterolemic drug target revisited. <b>2003</b> , 42, 37-50	225
668	Experimental model of postprandial hypertriglyceridemia in sucrose-fed rats and the effectiveness of atorvastatin in the model. <b>2003</b> , 52, 609-15	14
667	Treating dyslipidemia with statins: the risk-benefit profile. <b>2003</b> , 145, 387-96	46
666	Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. <b>2003</b> , 326, 1423	1155
665	Effects of statins on lipoprotein fractions. <b>2003</b> , 1253, 247-252	2
664	Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. <b>2003</b> , 54, 679-90	77
663	Ezetimibe: a novel option for lowering cholesterol. <b>2003</b> , 1, 11-21	30
662	Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. <b>2003</b> , 139, 97-104	114



661	Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. <b>2003</b> , 20, 153-63	46
660	Cardiovascular disease and lipids. Issues and evidence for the management of dyslipidaemia in primary care. <b>2003</b> , 9, 16-24	4
659	A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels. <b>2003</b> , 21 Suppl 1, 1-11	11
658	New drugs for the treatment of hypercholesterolaemia. <b>2003</b> , 12, 1777-89	24
657	Early vascular benefits of statin therapy. <b>2003</b> , 19, 540-56	132
656	Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. <b>2003</b> , 107, 3124-8	72
655	Review: Diabetic dyslipidaemia II the case for using statins. <b>2003</b> , 3, 402-407	
654	Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening. <b>2003</b> , 25, 47-52	25
653	Rosuvastatin--a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. <b>2003</b> , 99, 126-39	39
652	Magnitude of HDL cholesterol variation after high-dose atorvastatin is genetically determined at the LDL receptor locus in patients with homozygous familial hypercholesterolemia. <b>2003</b> , 23, 2078-82	3
651	Therapeutic considerations for the use of statin therapy in chronic renal disease. <b>2003</b> , 95, c107-15	4
650	Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. <b>2003</b> , 18, 967-76	91
649	Statin Treatment in Diabetes Mellitus. <b>2003</b> , 21, 168-172	21
648	Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. <b>2003</b> , 23, 769-75	281
647	Hemostatic effects of atorvastatin versus simvastatin. <b>2003</b> , 37, 478-84	17
646	Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. <b>2003</b> , 44, 1192-8	39
645	Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. <b>2003</b> , 326, 689	19
644	Originalpräparate versus Generika - Das Beispiel Statine. <b>2003</b> , 8, 307-313	

643	Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. <b>2003</b> , 88, 5341-7	46
642	Efficacy and Safety of Plant Stanols and Sterols in the Management of Blood Cholesterol Levels. <b>2003</b> , 78, 965-978	759
641	Benefits of aggressive drug therapy. <b>2003</b> , 18, 79-84	1
640	Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. <b>2003</b> , 18, 278-85	16
639	The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?. <b>2003</b> , 163, 333-9	38
638	Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients. <b>2003</b> , 67, 816-20	29
637	Pravastatin prevents arrhythmias induced by coronary artery ischemia/reperfusion in anesthetized normocholesterolemic rats. <b>2003</b> , 93, 87-94	41
636	Atorvastatin is an effective and well-tolerated treatment alternative for patients not achieving target lipid goals with simvastatin. <b>2003</b> , 43, 637-9	
635	Treating to target: using cost-effective statins. <b>2003</b> , 9, 305-309	
634	Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. <b>2003</b> , 10, 329-36	46
633	Weight uniformity of split tablets required by a Veterans Affairs policy. <b>2003</b> , 9, 401-7	30
632	Comparison of the effect of two HMG CoA reductase inhibitors on LDL susceptibility to oxidation. <b>2003</b> , 80, 156-61, 150-5	6
631	Long-term hemostatic effects of cholesterol-lowering therapy with atorvastatin. <b>2003</b> , 33, 84-7	7
630	Drug-related dyslipidemia after renal transplantation. <b>2004</b> , 61, 565-585	75
629	Statins for Primary Prevention: Strategic Options to Save Lives and Money. <b>2004</b> , 97, 66-71	1
628	Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <b>2004</b> , 20, 627-37	62
627	Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. <b>2004</b> , 27, 2887-92	82
626	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <b>2004</b> , 110, 227-39	445 <sup>o</sup>

625	The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: a review of findings to date. <b>2004</b> , 43, 595-606	71
624	Statin use after renal transplantation: a systematic quality review of trial-based evidence. <b>2004</b> , 19, 2378-86	33
623	Intensive treatment with statins and the progression of cardiovascular diseases: the beginning of a new era?. <b>2004</b> , 19, 2696-9	3
622	Approximate equivalent rosuvastatin doses for temporary statin interchange programs. <b>2004</b> , 38, 1286-92	29
621	Statins: can the new generation make an impression?. <b>2004</b> , 9, 269-79	19
620	Pharmacodynamic interaction between ezetimibe and rosuvastatin. <b>2004</b> , 20, 1185-95	45
619	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <b>2004</b> , 24, e149-61	181
618	Improving lipid management--to titrate, combine or switch. <b>2004</b> , 58, 689-94	20
617	The care gap: underuse of statin therapy in the elderly. <b>2004</b> , 58, 777-85	17
616	Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. <b>2004</b> , 58, 528-35	39
615	Comparative effects of lipid-lowering therapies. <b>2004</b> , 47, 73-104	83
614	A clinical comparison of calculated versus direct measurement of low-density lipoprotein cholesterol level. <b>2004</b> , 24, 167-72	35
613	Development and preliminary testing of a patient decision aid to assist pharmaceutical care in the prevention of cardiovascular disease. <b>2004</b> , 24, 909-22	36
612	Statin therapy is associated with lower mortality among patients with severe heart failure. <i>American Journal of Cardiology</i> , <b>2004</b> , 93, 1124-9	3 142
611	Optimizing lipid lowering in patients at risk. <b>2004</b> , 27, III22-6	2
610	Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromso study 2001. <b>2004</b> , 60, 643-9	16
609	Short-term effect of low-dose atorvastatin on haemorrhological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia. <b>2004</b> , 18, 165-72	34
608	Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. <b>2004</b> , 20, 1087-94	11

607	[Diagnosis and treatment of familial hyperlipaemia episodes]. <b>2004</b> , 34, 557-64	2
606	Estatinas: potencia, relaci3n coste-efectividad. Estudio comparativo. <b>2004</b> , 30, 142-146	
605	Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. <b>2004</b> , 173, 1-12	202
604	Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme. <b>2004</b> , 5, 1187-200	31
603	Effect of atorvastatin on different fibrinolysis mechanisms in hypercholesterolemic subjects. <b>2004</b> , 95, 269-74	35
602	Does aggressive statin therapy offer improved cholesterol-independent benefits compared to conventional statin treatment?. <b>2004</b> , 96, 131-9	9
601	Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. <b>2004</b> , 147, 705-13	125
600	Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options. <b>2004</b> , 148, S9-13	22
599	Low-density lipoprotein cholesterol reduction and cardiovascular disease prevention: the search for superior treatment. <b>2004</b> , 116 Suppl 6A, 17S-25S	18
598	Cholesterol management and the reduction of cardiovascular risk. <b>2004</b> , 7, 34-9; quiz 40-1	9
597	Coronary heart disease risk reduction in postmenopausal women: the role of statin therapy and hormone replacement therapy. <b>2004</b> , 7, 131-6	1
596	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <b>2004</b> , 44, 720-32	1070
595	Lipid-lowering therapy: strategies for improving compliance. <b>2004</b> , 20, 165-73	15
594	Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. <b>2004</b> , 173, 55-68	364
593	Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. <b>2004</b> , 175, 325-31	39
592	Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects. <b>2004</b> , 177, 89-96	27
591	F3macos hipolipemiantes. <b>2004</b> , 9, 1122-1130	
590	Dyslipidemia in the metabolic syndrome. <b>2004</b> , 2, 3-34	1

589	Lipid-lowering response to statins is affected by CYP3A5 polymorphism. <b>2004</b> , 14, 523-5		148
588	Statins for primary prevention: strategic options to save lives and money. <b>2004</b> , 97, 66-71		1
587	Optimizing LDL-C lowering with statins. <b>2004</b> , 11, 54-9		21
586	Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods. <b>2004</b> , 107, 233-49		40
585	Effect of a new beta-sitosterol analogue on plasma lipid concentrations in rats. <b>2004</b> , 52, 597-601		5
584	Torcetrapib/atorvastatin combination therapy. <b>2005</b> , 3, 789-820		25
583	Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia. <b>2005</b> , 15, 211-8		24
582	Model-based development of gemcabene, a new lipid-altering agent. <b>2005</b> , 7, E513-22		55
581	Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. <b>2005</b> , 19, 117-25		725
580	Suboptimal choices and dosing of statins at start of therapy. <b>2005</b> , 60, 83-9		19
579	Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. <b>2005</b> , 60, 543-51		136
578	Effect of statins on noncholesterol sterol levels: implications for use of plant stanols and sterols. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 40D-46D	3	31
577	High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 50K-58K; discussion 34K-35K	3	69
576	Cost-efficacy analysis of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors based on results of the STELLAR trial: clinical implications for therapeutic selection. <b>2005</b> , 25, 270-8		11
575	Achieving cholesterol target in a managed care organization (ACTION) trial. <b>2005</b> , 25, 360-71		22
574	Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins. <b>2005</b> , 20, 217-23		7
573	Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. <b>2005</b> , 48, 1105-13		40
572	Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs. <b>2005</b> , 22, 1578-88		58

571	[Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits]. <b>2005</b> , 84, 314-9		13
570	Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization. <b>2005</b> , 11, 681-6		16
569	Cost-Effectiveness Analysis of Combination Statin/Ezetimibe Therapy for the Treatment of Elevated Low-Density Lipoprotein Cholesterol. <b>2005</b> , 40, 687-692		0
568	[Ezetimibe--pharmacokinetics and therapeutics]. <b>2005</b> , 85 Suppl 5, 20-4		2
567	The status of lipid management in 1,836 patients with coronary artery disease: a multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low-density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society. <b>2005</b> , 12, 338-42		14
566	The predictive value of lipid markers in vascular disease. <b>2005</b> , 11, 2209-24		8
565	New lipid-lowering agents acting on LDL receptors. <b>2005</b> , 5, 233-42		34
564	National trends in statin use by coronary heart disease risk category. <b>2005</b> , 2, e123		94
563	Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia. <b>2005</b> , 62, 2491-4		19
562	Statins: immunomodulators for autoimmune rheumatic disease?. <b>2005</b> , 14, 192-6		29
561	[Lipid metabolism and risk of myocardial infarction -- new findings and implications for treatment]. <b>2005</b> , 130, 2220-5		
560	Rosuvastatin: achieving cholesterol targets. <b>2005</b> , 1, 289-97		
559	Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. <i>Cmaj</i> , <b>2005</b> , 172, 1187-94	3-5	42
558	Use of fluvastatin following percutaneous coronary intervention. <b>2005</b> , 5, 113-23		4
557	Over-the-counter statins: a new controversy. <b>2005</b> , 2, 174-5		5
556	Atorvastatin: An Update of Recent Clinical Trial Experience. <b>2005</b> , 21, 197-202		
555	Comparison of pre- and postsurgical concentrations of blood HER-2 mRNA and HER-2 extracellular domain reflects HER-2 status in early breast cancer. <b>2005</b> , 51, 254-6		4
554	Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. <b>2005</b> , 19, 804-6		116

553	Statin therapy has no significant effect on skin tissue cholesterol: results from a prospective randomized trial. <b>2005</b> , 51, 252-4	14
552	Treatment of dyslipidaemia in HIV-infected persons. <b>2005</b> , 6, 1619-45	9
551	The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development. <b>2005</b> , 21 Suppl 6, S17-22	12
550	Over the counter statins a good idea?. <b>2005</b> , 5, 51-53	2
549	Lipid and non-lipid effects of statins. <b>2005</b> , 365-88	9
548	Mechanisms for antiplatelet action of statins. <b>2005</b> , 5, 121-6	18
547	Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 2/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada. <b>2005</b> , 112, 1296-300	22
546	Review: Defining the role of statins in diabetes. <b>2005</b> , 5, 55-62	1
545	Manejo terapéutico de la arteriosclerosis. <b>2005</b> , 9, 2536-2541	
544	Coste del tratamiento farmacológico del paciente diabético tipo 2. <b>2005</b> , 31, 204-209	1
543	A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. <b>2005</b> , 80, 587-95	212
542	[Statins and prevention of strokes]. <b>2005</b> , 161, 237-44	2
541	Toxic myopathies. <b>2005</b> , 23, 397-428	56
540	Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study. <b>2005</b> , 80, 1163-8	19
539	A pharmaco-economic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain. <b>2005</b> , 23, 275-87	10
538	Dieci anni di utilizzo delle statine: adesione alla terapia e costi del trattamento farmacologico. <b>2005</b> , 7, 187-194	4
537	Fluvastatin: efficacy and safety in reducing cardiac events. <b>2005</b> , 6, 1883-95	2
536	Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. <b>2005</b> , 312, 786-93	152

535	Statins and fibrates for preventing melanoma. <b>2005</b> , CD003697	25
534	Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). <b>2005</b> , 7, 264-73	58
533	Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the Avall polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment. <b>2005</b> , 54, 741-7	19
532	Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates. <b>2005</b> , 101, 293-8	30
531	Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. <b>2005</b> , 104, 338-45	22
530	Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. <b>2005</b> , 27, 174-84	55
529	Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry. <b>2005</b> , 115, 263-70	31
528	Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients. <b>2005</b> , 37, 3808-12	19
527	Cardiovascular functional phenotypes and pharmacological responses in apolipoprotein E deficient mice. <b>2005</b> , 26, 309-16	34
526	Small hippocampal size in cognitively normal subjects with coronary artery disease. <b>2005</b> , 26, 865-71	30
525	Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes. <b>2005</b> , 315, 363-9	33
524	Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. <b>2005</b> , 150, 859-70	64
523	Low HDL-C: a secondary target of dyslipidemia therapy. <b>2005</b> , 118, 1067-77	58
522	Barriers to effective implementation of guideline recommendations. <b>2005</b> , 118 Suppl 12A, 36-41	54
521	[Objective-oriented planification in the treatment of hypercholesterolemia]. <b>2005</b> , 124, 108-10	7
520	Inhibidores de la absorci3n del colesterol. <b>2005</b> , 52, 297-308	1
519	A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. <b>2005</b> , 352, 2389-97	753
518	Atherosclerosis: Diet and Drugs. <b>2005</b> ,	2



517	The Performance Gap between Clinical Trials and Patient Treatment for Dyslipidemia. <b>2005</b> , 13, 255-265	3
516	Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholesterolemic subjects. <b>2005</b> , 11, 417-28	24
515	Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials. <b>2005</b> , 6, 915-27	19
514	Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. <b>2006</b> , 4, 461-76	37
513	Cost-effectiveness analysis of cholesterol-lowering therapies in Spain. <b>2006</b> , 6, 177-88	10
512	Comparative efficacy and safety of atorvastatin, simvastatin and lovastatin in the management of dyslipidemic Type 2 diabetic patients. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2006</b> , 3, 759-764	6
511	The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention. <b>2006</b> , 22, 419-23	1
510	Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. <b>2006</b> , 46, 1030-7	20
509	[Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia]. <b>2006</b> , 127, 250-2	6
508	Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. <b>2006</b> , 151, 273-81	93
507	Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization. <b>2006</b> , 28, 591-9	22
506	Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol. <b>2006</b> , 8, 493-9; quiz 500-1	4
505	Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. <b>2006</b> , 408, 189-93	24
504	Statins for Treatment of Dyslipidemia in Chronic Kidney Disease. <b>2006</b> , 26, 523-539	53
503	Association between the dosage and duration of statin treatment with coronary collateral development. <b>2006</b> , 17, 561-5	14
502	Ezetimibe: one step beyond in the battle against atherosclerosis. <b>2006</b> , 1, 255-266	1
501	Role of Thyroid Disease in the Development of Statin-Induced Myopathy. <b>2006</b> , 16, 279-285	12
500	Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. <b>2006</b> , 20, 321-30	19

499	Management of lipid abnormalities associated with end-stage renal disease. <b>2006</b> , 19, 391-401		1
498	Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. <b>2002</b> , 20, 303-28		132
497	Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs. <b>2006</b> , 36, 224-30		14
496	Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. <b>2006</b> , 149, 909-19		43
495	High-density lipoproteins: an emerging target in the prevention of cardiovascular disease. <b>2006</b> , 16, 799-808		16
494	Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. <b>2006</b> , 79, 419-26		89
493	Lipid-lowering treatment: today's recommended management. <b>2006</b> , 17, 33-44		1
492	The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention. <b>2006</b> , 20, 309-17		12
491	Effect of pravastatin on plasma sterols and oxysterols in men. <b>2006</b> , 62, 9-14		27
490	Are lower levels of low-density lipoprotein cholesterol beneficial? a review of recent data. <b>2006</b> , 8, 382-9		1
489	The CARDS trial: diabetic patients dealt a winning hand. <b>2006</b> , 8, 429-32		8
488	Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. <i>American Journal of Cardiology</i> , <b>2006</b> , 97, 229-35	3	58
487	Effect of statin treatment on coronary collateral development in patients with diabetes mellitus. <i>American Journal of Cardiology</i> , <b>2006</b> , 97, 772-4	3	16
486	Statin safety and drug interactions: clinical implications. <i>American Journal of Cardiology</i> , <b>2006</b> , 97, 27C-31C		140
485	Doble inhibici3n del colesterol: papel de la regulaci3n intestinal y hep3tica. <b>2006</b> , 6, 52G-62G		1
484	Beneficios de la terapia combinada en la hiperlipemia. <b>2006</b> , 6, 63G-71G		0
483	Comparison of Atorvastatin and Simvastatin in the Long-term Treatment of Hyperlipidemia After Kidney Transplantation. <b>2006</b> , 8, 17-23		0
482	Pharmacological regulation of low density lipoprotein receptor expression: current status and future developments. <b>2006</b> , 111, 424-33		12

481	Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. <b>2006</b> , 26, 469-78	42
480	Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. <b>2006</b> , 20, 924-36	42
479	Options for therapeutic intervention: how effective are the different agents?. <b>2006</b> , 8, F47-F53	9
478	Statins: Are They All the Same?. <b>2006</b> , 1, 157-172	
477	Switching statins. <b>2006</b> , 332, 1344-5	37
476	Effect of atorvastatin on type 2 diabetic dyslipidemia. <b>2006</b> , 11, 262-70	17
475	Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions. <b>2006</b> , 4, 253-68	8
474	Statin use and breast cancer: prospective results from the Women's Health Initiative. <b>2006</b> , 98, 700-7	146
473	Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. <b>2006</b> , 47, 1281-8	247
472	Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. <b>2006</b> , 295, 2262-9	129
471	Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. <b>2006</b> , 176, 5284-92	69
470	Dyslipidemia. <b>2006</b> ,	
469	Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. <b>2006</b> , 26, 1094-100	199
468	Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting. <b>2007</b> , 64, 276-84	13
467	Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin. <b>2007</b> , 293, L463-71	46
466	Contemporary diagnosis and management of hypercholesterolemia in elderly acute myocardial infarction patients: a population-based study. <b>2007</b> , 16, 15-23	5
465	Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. <b>2007</b> , 93, 945-51	22
464	The 'forgotten' bile acid sequestrants: is now a good time to remember?. <b>2007</b> , 14, 567-80	75

463	The effect of statins on postprandial lipemia. <b>2007</b> , 8, 551-60	25
462	Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. <b>2007</b> , 8, 483-8	23
461	Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation?. <b>2007</b> , 39, 2259-63	4
460	Statins and C-reactive protein levels. <b>2007</b> , 9, 622-8	34
459	Hypertriglyceridemia and cardiovascular risk reduction. <b>2007</b> , 29, 763-777	97
458	Is lipid lowering treatment aiming for very low LDL levels safe in terms of the synthesis of steroid hormones?. <b>2007</b> , 69, 104-12	11
457	Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. <b>2007</b> , 191, 135-46	29
456	Statin-associated adverse effects beyond muscle and liver toxicity. <b>2007</b> , 195, 7-16	86
455	Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. <b>2007</b> , 194, e154-64	45
454	Efecto, en la práctica clínica, de la fluvastatina de liberación prolongada en los lípidos séricos en pacientes con diabetes tipo 2 y dislipemia. <b>2007</b> , 19, 240-246	0
453	Statin wars following coronary revascularization - evidence-based clinical practice?. <b>2007</b> , 23, 319; author reply 319	
452	Atorvastatin: pharmacological characteristics and lipid-lowering effects. <b>2007</b> , 67 Suppl 1, 3-15	38
451	Colesevelam. <b>2007</b> , 7, 471-483	
450	Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events. <b>2007</b> , 25, 1031-53	13
449	Colesevelam: a review of its use in hypercholesterolemia. <b>2007</b> , 7, 453-65	16
448	Effects of treatment with a commercially available St John's Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin. <b>2007</b> , 25, 154-9	16
447	Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus. <b>2007</b> , 64, 1603-10	9
446	Statin wars: emphasis on potency vs event reduction and safety?. <b>2007</b> , 82, 539-42	20

445	Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review. <b>2007</b> , 27, 591-604	15
444	Effect of drugs on high-density lipoprotein. <b>2007</b> , 1, 74-87	3
443	Comparison of Efficacy and Safety after Administering High Potency Statin to High Risk Patients: Rosuvastatin 10 mg versus Atorvastatin 20 mg. <b>2007</b> , 37, 154	12
442	Statins and risk of cancer: a systematic review and metaanalysis. <b>2007</b> , 120, 833-43	177
441	The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. <b>2007</b> , 40, 1-5	46
440	Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. <b>2007</b> , 16, 385-92	25
439	Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. <b>2007</b> , 81, 650-3	82
438	Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. <b>2007</b> , 24, 541-9	32
437	HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. <b>2007</b> , 37, 852-9	35
436	Impact of adherence to statins on coronary artery disease in primary prevention. <b>2007</b> , 63, 698-708	74
435	Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting. <b>2007</b> , 61, 15-23	33
434	Response to Study highlights need for considered clinical approach to statin switching. <b>2007</b> , 61, 881-882	
433	Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus. <b>2007</b> , 27, 845-51	27
432	Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. <b>2007</b> , 52, 503-9	42
431	Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 681-5	3 69
430	Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 1E-35E	3 18
429	From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention. <b>2007</b> , 113, 184-96	35
428	The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. <b>2007</b> , 50, 791-802	35

427	Intensive statins post-MI: best practice vs cost-effective prescribing. <b>2007</b> , 18, 9-10	
426	Mevalonate pathway: a review of clinical and therapeutical implications. <b>2007</b> , 40, 575-84	360
425	The effects of zoledronic acid on serum lipids in multiple myeloma patients. <b>2008</b> , 82, 258-62	18
424	Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. <b>2008</b> , 62, 480-4	52
423	Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. <b>2008</b> , 62, 539-54	23
422	Effects of plant sterol and stanol ester consumption on lipid metabolism, antioxidant status and markers of oxidative stress, endothelial function and low-grade inflammation in patients on current statin treatment. <b>2008</b> , 62, 263-73	96
421	Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (Eflucimibe): could it be a new antiatherosclerotic therapeutic?. <b>2008</b> , 26, 65-74	7
420	Ezetimibe effectively lowers LDL-cholesterol in cardiac allograft recipients on stable statin therapy. <b>2008</b> , 22, 639-44	4
419	Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. <b>2008</b> , 28, 553-61	24
418	Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy. <b>2008</b> , 28, 913-9	11
417	Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. <b>2008</b> , 57, 246-54	44
416	Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. <b>2008</b> , 57, 380-6	38
415	Combination of simvastatin with berberine improves the lipid-lowering efficacy. <b>2008</b> , 57, 1029-37	126
414	Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. <b>2008</b> , 47, 463-74	145
413	[Rational and efficient use of treatment with statins]. <b>2008</b> , 130, 263-6	1
412	Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. <b>2008</b> , 2, 426-35	42
411	Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. <b>2008</b> , 24, 1217-29	28
410	Primary Prevention and Statins: Is It Just About Going to Class?. <b>2008</b> , 83, 1313-1315	1

409 Cardiology. **2008**, 95-126

408 Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. **2008**, 30, 84-97 15

407 Class effects of statins in elderly patients with congestive heart failure: a population-based analysis. **2008**, 155, 316-23 25

406 Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia. **2008**, 19, 203-8 4

405 Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. **2008**, 30, 195-205 33

404 Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. **2008**, 30, 2167-79 119

403 A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in diabetic patients without prior cardiovascular disease. **2008**, 82, e13-5 1

402 (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxy-1H-benzofuran-4-carboxamide (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential. **2008**, 51, 2722-33 28

401 Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). **2008**, 197, 420-7 12

400 Novel aspects of postprandial lipemia in relation to atherosclerosis. **2008**, 9, 39-44 77

399 Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated. **2008**, 83, 1316-1325 21

398 Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice. **2008**, 24, 2777-84 3

397 Preparation of a HMG-CoA Reductase Inhibitor via an Optimized Imidazole-Forming Condensation Reaction. **2008**, 12, 1183-1187 7

396 Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. **2008**, 68, 5246-56 175

395 Challenges to evidence-based prescribing in clinical practice. **2008**, 42, 704-7 10

394 Can cheap generic statins achieve national cholesterol lowering targets?. **2008**, 13, 99-102 4

393 Prescription drug spending trends in the United States: looking beyond the turning point. **2009**, 28, w151-60 91

392 Statin use and incident frailty in women aged 65 years or older: prospective findings from the Women's Health Initiative Observational Study. **2008**, 63, 369-75 68

391	Strategies for prescribing statins. <b>2008</b> , 336, 288-9	6
390	Improving access to research data in Europe. <b>2008</b> , 336, 287-8	8
389	Involving users in developing health services. <b>2008</b> , 336, 286-7	20
388	Ezetimibe plus simvastatin cardiovascular outcomes study program. <b>2008</b> , 6, 17-25	3
387	Niacin: a lipid polypill?. <b>2008</b> , 9, 2911-20	6
386	Malnutrition in hospitals. <b>2008</b> , 336, 290	44
385	Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes. <b>2008</b> , 13, 183-8	5
384	The influence of statin medications on prostate-specific antigen levels. <b>2008</b> , 100, 1511-8	126
383	Targeted versus global approaches to the management of hypercholesterolaemia. <b>2008</b> , 128, 248-54	3
382	Treatment of coronary spastic angina with a statin in addition to a calcium channel blocker: a pilot study. <b>2008</b> , 52, 28-34	15
381	Sugary drinks, fruit, and increased risk of gout. <b>2008</b> , 336, 285-6	6
380	Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. <b>2008</b> , 86, 1771-6	19
379	Systemic lupus erythematosus in a multiethnic US cohort, LUMINA (XLIX): preliminary evaluation of the impact of statins on disease activity. <b>2008</b> , 14, 178-80	4
378	Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. <b>2008</b> , 86, 245-50	36
377	Can HMG Co-A reductase inhibitors ("statins") slow the progression of age-related macular degeneration? The age-related maculopathy statin study (ARMSS). <b>2008</b> , 3, 581-93	20
376	Safety and tolerability of fluvastatin XL in the treatment of hyper-cholesterolemia : a postmarketing surveillance conducted in Indonesia. <b>2008</b> , 88	1
375	[Raising HDL cholesterol: which is the best strategy?]. <b>2008</b> , 54, 369-76	3
374	Clinical efficacy and safety of statins in managing cardiovascular risk. <i>Vascular Health and Risk Management</i> , <b>2008</b> , 4, 341-53	4.4 89



373	High-density lipoproteins: the next frontier in lipid management. <b>2008</b> , 189, 421-2	1
372	Preferred drug lists: potential impact on healthcare economics. <i>Vascular Health and Risk Management</i> , <b>2008</b> , 4, 403-13	4-4 10
371	Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. <b>2009</b> , 150, 301-13	75
370	Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics. <b>2009</b> , 1, 25-33	9
369	Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?. <b>2010</b> , 3, 1-11	
368	Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease. <b>2009</b> , 7, 1-26	16
367	Fundamental cause theory, technological innovation, and health disparities: the case of cholesterol in the era of statins. <b>2009</b> , 50, 245-60	113
366	Improving abnormal hemorheological parameters in ApoE <sup>-/-</sup> mice by Ilex kudingcha total saponins. <b>2009</b> , 42, 29-36	10
365	Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. <b>2009</b> , 37, 1129-37	53
364	Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors. <b>2009</b> , 83, 595-603	28
363	Continuation of statin treatment and all-cause mortality: a population-based cohort study. <b>2009</b> , 169, 260-8	111
362	Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions. <b>2009</b> , 31, 2919-30; discussion 2916-8	13
361	Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. <i>American Journal of Cardiology</i> , <b>2009</b> , 103, 437-41	3 61
360	Achieving optimum lipid-lowering goals in patients with vascular disease. <b>2009</b> , 3, 323-330	
359	Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland. <b>2009</b> , 65, 927-33	7
358	Impact of better adherence to statin agents in the primary prevention of coronary artery disease. <b>2009</b> , 65, 1013-24	75
357	Update on statin-mediated anti-inflammatory activities in atherosclerosis. <b>2009</b> , 31, 127-42	64
356	Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice. <b>2009</b> , 18, 1214-22	8

355	Slight of hand in trial design: average behaviour is not average, not all new information is really new. <b>2009</b> , 63, 534-5	2
354	A new statin: a new standard. <b>2001</b> , 24, III18-23	3
353	Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. <b>2009</b> , 25, 2755-64	62
352	Occurrence and fate of rosuvastatin, rosuvastatin lactone, and atorvastatin in Canadian sewage and surface water samples. <b>2009</b> , 77, 1285-91	33
351	Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin. <b>2009</b> , 28, 598-604	12
350	Effect of statin adherence on cerebrovascular disease in primary prevention. <b>2009</b> , 122, 647-55	49
349	A significant temporal and quantitative relationship exists between high-density lipoprotein levels and acute ischemic stroke presentation. <b>2009</b> , 279, 53-6	7
348	Utilidad de la citometría de flujo para valorar el efecto de la atorvastatina sobre la función plaquetaria y la movilización del Ca <sup>2+</sup> en pacientes hiperlipémicos. <b>2009</b> , 2, 73-79	
347	Analysis of recently identified dyslipidemia alleles reveals two loci that contribute to risk for carotid artery disease. <b>2009</b> , 8, 52	27
346	Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population. <b>2009</b> , 84, 1065-72	17
345	Endothelium function, lipid peroxidation, plasmatic and tissue cholesterol evaluations in mixed dyslipidemia in rabbits treated with rosuvastatin and atorvastatin. <b>2009</b> , 21, 263-267	1
344	Clinical determinants of infarct pattern subtypes in large vessel atherosclerotic stroke. <b>2009</b> , 256, 591-9	17
343	Insufficient statin therapy in coronary heart disease is related to the time of the last coronary angiography. <b>2009</b> , 53, 215-22	
342	Triglycerides and vascular risk: insights from epidemiological data and interventional studies. <b>2009</b> , 10, 320-7	23
341	Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol. <b>2010</b> , 17, 167-75	25
340	Atherosclerosis I: LDL Cholesterol Lowering. <b>2010</b> , 303-330	
339	Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. <b>2000</b> , 15, 599-604	59
338	Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?. <b>2010</b> , 11, 959-71	5

- 337 The statins: a drug class to celebrate. **2010**, 1, 14-17
- 336 Protein-nanoparticle conjugates as potential therapeutic agents for the treatment of hyperlipidemia. **2010**, 21, 265103 27
- 335 [New aspects of perioperative statin therapy]. **2010**, 59, 539-48 3
- 334 Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. **2010**, 27, 348-64 18
- 333 Hyperlipidemia and primary prevention of stroke: does risk factor identification and reduction really work?. **2010**, 12, 225-9 20
- 332 [Therapeutic drug option for dyslipaemia]. **2010**, 42, 115-20 0
- 331 Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. **2010**, 32, 1396-407 22
- 330 Clinical and economic outcomes in patients switched to simvastatin in a community-based family medicine practice. **2010**, 64, 1235-8 7
- 329 A systematic review and meta-analysis on the therapeutic equivalence of statins. **2010**, 35, 139-51 210
- 328 Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. **2010**, 17, 436-51 68
- 327 Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. **2010**, 38, 1499-504 108
- 326 LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice. **2010**, 122, 16-24 29
- 325 Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. **2010**, 30, 1485-92 52
- 324 Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. **2010**, 340, c2197 351
- 323 Effects of concomitant therapy with diltiazem on the lipid responses to simvastatin in Chinese subjects. **2010**, 50, 1151-8 7
- 322 Phytosterols for dyslipidemia. **2010**, 67, 1165-73 28
- 321 Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. **2010**, 26, 2301-13 20
- 320 Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes. **2010**, 5, 856-66 13

319	Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. <b>2010</b> , 7, e1000336	68
318	A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study. <i>Cmaj</i> , <b>2010</b> , 182, 447-55	3-5 36
317	Incomparable effectiveness--apples to apples?. <b>2010</b> , 85, 764; author reply 764-6	
316	Incomparable EffectivenessApples to Apples?Reply <b>2010</b> , 85, 764-767	78
315	Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study. <b>2010</b> , 30, 157-66	3
314	Persistence with statins and incident cataract: a population-based historical cohort study. <b>2010</b> , 20, 136-42	38
313	Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. <b>2011</b> , 41, 639-51	45
312	Spectrophotometric determination of atorvastatin and amlodipine by H-point standard addition method with simultaneous addition of both analytes in nonaqueous solution. <b>2011</b> , 76, 193-205	2
311	Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <b>2011</b> , 5, S38-45	102
310	Therapeutic Lifestyle Change for the Prevention and Treatment of Hyperlipidemia and Coronary Artery Disease. <b>2011</b> , 105-120	
309	Pharmacogenomic Testing in Current Clinical Practice. <b>2011</b> ,	1
308	Activating peripheral arterial disease patients to reduce cholesterol: a randomized trial. <b>2011</b> , 124, 557-65	16
307	Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin. <b>2011</b> , 9, 471-82	6
306	Statin-associated rhabdomyolysis: is there a dose-response relationship?. <b>2011</b> , 27, 146-51	51
305	The impact of direct-to-consumer advertising of prescription drugs on physician visits and drug requests: Empirical findings and public policy implications. <b>2011</b> , 28, 205-217	51
304	Protective effect of lycopene on serum cholesterol and blood pressure: Meta-analyses of intervention trials. <b>2011</b> , 68, 299-310	135
303	[Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study]. <b>2011</b> , 64, 286-94	50
302	[Benefits of statin therapy based on plasma carbohydrate antigen 125 values following an admission for acute heart failure]. <b>2011</b> , 64, 1100-8	9

301	Statins for the primary prevention of cardiovascular disease. <b>2011</b> , CD004816	178
300	The "top 5" lists in primary care: meeting the responsibility of professionalism. <b>2011</b> , 171, 1385-90	104
299	Prevalence and Characteristics of Lipid Abnormalities in Patients Treated With Statins in Primary and Secondary Prevention in Spain. DYSIS-Spain Study. <b>2011</b> , 64, 286-294	0
298	Benefits of Statin Therapy Based on Plasma Carbohydrate Antigen 125 Values Following an Admission for Acute Heart Failure. <b>2011</b> , 64, 1100-1108	1
297	Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. <b>2011</b> , 217, 458-64	32
296	Carriage of the V279F null allele within the gene encoding Lp-PLA <sub>2</sub> s protective from coronary artery disease in South Korean males. <b>2011</b> , 6, e18208	37
295	A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in hypertensive patients without prior cardiovascular disease. <b>2011</b> , 18, 110-6	1
294	Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. - From the viewpoint of cholesterol metabolism.-. <b>2011</b> , 75, 2496-504	15
293	Angiotensin-converting enzyme inhibitor and statin use and incident mobility limitation in community-dwelling older adults: the Health, Aging and Body Composition study. <b>2011</b> , 59, 2226-32	22
292	Differences between South Asians and White Europeans in five year outcome following percutaneous coronary intervention. <b>2011</b> , 65, 1259-66	16
291	The influence of dosing time, variable compliance and circadian low-density lipoprotein production on the effect of simvastatin: simulations from a pharmacokinetic-pharmacodynamic model. <b>2011</b> , 109, 494-8	9
290	Atorvastatin acts synergistically with N-acetyl cysteine to provide therapeutic advantage against Fas-activated erythrocyte apoptosis during chronic arsenic exposure in rats. <b>2011</b> , 250, 39-53	14
289	Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer. <b>2011</b> , 82, 1079-89	9
288	Development of an Early Enabling Synthesis for PF-03052334-02: A Novel Hepatoselective HMG-CoA Reductase Inhibitor. <b>2011</b> , 15, 148-157	17
287	Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: method development, validation and optimization of various experimental parameters. <b>2011</b> , 879, 557-63	53
286	Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk. <b>2011</b> , 18, 436-48	3
285	Gender differences in cholesterol-lowering medication prescribing in peripheral artery disease. <b>2011</b> , 16, 428-35	10
284	Lipid-lowering drug therapy in elderly patients. <b>2011</b> , 17, 877-93	18

283	The "top 5" health care activities for which less is more: comment on "The 'top 5' lists in primary care". <b>2011</b> , 171, 1390	
282	Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. <b>2011</b> , 103, 674-88	74
281	The ezetimibe controversy: implications for clinical practice. <b>2011</b> , 5, 199-208	12
280	Hyperlipidemia in Primary Care. <b>2011</b> ,	1
279	Statin use and the risk of age related macular degeneration in a large health organization in Israel. <b>2011</b> , 18, 83-90	22
278	A comparative effect of atorvastatin with other statins in patients of hyperlipidemia. <b>2012</b> , 44, 261-3	11
277	Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration. <b>2012</b> , 40, 663-7	6
276	Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review. <b>2012</b> , 124, 7-20	7
275	Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice. <b>2012</b> , 1, e22	48
274	HMG-CoA reductase inhibitors (statins) reduce hypertrophic scar formation in a rabbit ear wounding model. <b>2012</b> , 129, 252e-261e	37
273	Targeting tumor cell metabolism with statins. <b>2012</b> , 31, 4967-78	156
272	Oral simvastatin reduces the hypertensive response to air-jet stress. <b>2012</b> , 39, 350-6	3
271	The high-dose rosuvastatin once weekly study (the HD-ROWS). <b>2012</b> , 6, 362-7	10
270	Eficacia bioquímica y beneficio clínico de la doble inhibición con ezetimiba y simvastatina. <b>2012</b> , 12, 2-7	
269	American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. <b>2012</b> , 18 Suppl 1, 1-78	312
268	Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. <b>2012</b> , 22, 17-27	36
267	Dose-dependent Effect of Statin Therapy on Circulating CXCL12 Levels in Patients with Hyperlipidemia. <b>2012</b> , 1, 23	20
266	Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. <b>2012</b> , 72, 2365-73	69

265	Lipid lowering efficacy of atorvastatin. <b>2012</b> , 12, CD008226	27
264	Dyslipidemia. <b>2012</b> , 159-178	
263	Factors explaining the gender disparity in lipid-lowering treatment goal attainment rate in Chinese patients with statin therapy. <b>2012</b> , 11, 59	19
262	Differential mitochondrial toxicity screening and multi-parametric data analysis. <b>2012</b> , 7, e45226	35
261	Screening for lipid disorders. <b>2012</b> , 44, 115-21	2
260	Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs?. <b>2012</b> , 18, 954-64	23
259	Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece. <b>2012</b> , 4, 135-43	5
258	Prospective analysis of association between use of statins and melanoma risk in the Women's Health Initiative. <b>2012</b> , 118, 5124-31	23
257	Highly upregulated expression of CD36 and MSR1 in circulating monocytes of patients with acute coronary syndromes. <b>2012</b> , 31, 511-8	28
256	Influence of atorvastatin on the pharmacodynamic and pharmacokinetic activity of repaglinide in rats and rabbits. <b>2012</b> , 364, 159-64	5
255	Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. <b>2012</b> , 34, 190-9	69
254	Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia. <b>2012</b> , 37, 166-72	9
253	Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. <b>2013</b> , 12, 9	13
252	Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies. <b>2013</b> , 85, 84-94	129
251	New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?. <b>2013</b> , 27, 559-67	94
250	Gender Difference in Statin Intervention on Blood Lipid Control among Patients with Coronary Heart Disease. <b>2013</b> , 7, 116-121	5
249	Clinical efficacy of subgingivally delivered 1.2% atorvastatin in chronic periodontitis: a randomized controlled clinical trial. <b>2013</b> , 84, 871-9	42
248	Lipid-lowering agents. <b>2013</b> , 18, 401-11	23

247	[Diagnostic and treatment of familial hypercholesterolemia (FH) in adult: guidelines from the New French Society of Atherosclerosis (NSFA)]. <b>2013</b> , 42, 930-50	19
246	Extended-release niacin/laropiprant for lipid management: observational study in clinical practice. <b>2013</b> , 67, 527-35	2
245	Changes in preventive medical therapies and CV risk factors after CT angiography. <b>2013</b> , 6, 574-81	48
244	Impact of interpretative commenting on lipid profiles in people at high risk of familial hypercholesterolaemia. <b>2013</b> , 422, 21-5	29
243	Statins for the primary prevention of cardiovascular disease. <b>2013</b> , CD004816	490
242	Palladium-Catalyzed Cross-Coupling Reactions [Industrial Applications]. <b>2013</b> , 445-489	22
241	Preventive effects of p-coumaric acid on cardiac hypertrophy and alterations in electrocardiogram, lipids, and lipoproteins in experimentally induced myocardial infarcted rats. <b>2013</b> , 60, 348-54	26
240	Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. <b>2013</b> , 13, 631-42	105
239	Statin use and clinical outcomes in older men: a prospective population-based study. <b>2013</b> , 3,	37
238	[Evidence based check-up: the general medical point of view]. <b>2013</b> , 102, 647-56	2
237	Prospective analysis of association between statin use and breast cancer risk in the women's health initiative. <b>2013</b> , 22, 1868-76	35
236	Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. <i>European Heart Journal</i> , <b>2013</b> , 34, 982-92	9.5 78
235	Three-Dimensional Structure of Xanthones. <b>2013</b> , 371-414	
234	Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy. <b>2013</b> , 57, 513-9	12
233	Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <b>2013</b> , 19, 139-49	79
232	Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. <b>2013</b> , 20, 245-56	6
231	Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. <b>2014</b> , 6, 71	34
230	Effect of Atorvastatin on Pharmacology of Sitagliptin in Streptozotocin-Nicotinamide Induced Type-II Diabetes in Rats. <b>2014</b> , 07,	



229	Brand Name Statin Prescribing in a Resident Ambulatory Practice: Implications for Teaching Cost-Conscious Medicine. <b>2014</b> , 6, 484-8	8
228	Comparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells. <b>2014</b> , 90, 44	7
227	Managing recalcitrant hypercholesterolemia in patients on current best standard of care: efficacy and safety of novel pharmacotherapies. <b>2014</b> , 9, 221-233	10
226	Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. <b>2014</b> , 66, 1619-26	55
225	Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe. <b>2014</b> , 5, 261	8
224	Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. <b>2014</b> , 8, 568-575	39
223	Factors Influencing the Increasing Disparity in LDL Cholesterol Control Between White and Black Patients With Diabetes in a Context of Active Quality Improvement. <b>2014</b> , 29, 308-14	2
222	Role of statin in atrial fibrillation-related stroke: an angiographic study for collateral flow. <b>2014</b> , 37, 77-84	32
221	Use of ezetimibe results in more patients reaching lipid targets without side effects. <b>2014</b> , 56, e128-e132	3
220	Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets. <b>2014</b> , 72, 18-29	78
219	Simvastatin treatment highlights a new role for the isoprenoid/cholesterol biosynthetic pathway in the modulation of emotional reactivity and cognitive performance in rats. <b>2014</b> , 39, 841-54	33
218	Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database. <b>2014</b> , 23, 240-50	22
217	Efficacy and safety of pitavastatin versus simvastatin: a meta-analysis of randomized controlled trials. <b>2014</b> , 34, 599-608	7
216	Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. <b>2014</b> , 50, 2822-30	52
215	A simple and effective approach for the treatment of dyslipidemia using anionic nanoliposomes. <b>2014</b> , 122, 645-652	5
214	Statin treatment and new-onset diabetes: a review of proposed mechanisms. <b>2014</b> , 63, 735-45	144
213	Comparison of lipid management in patients with coronary versus peripheral arterial disease. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1320-5	3 18
212	Impact of live medication therapy management on cholesterol values in patients with cardiovascular disease. <b>2014</b> , 54, 526-9	5

211	Metabolic and Endocrine Management of the Organ Transplant Recipient. <b>2014</b> , 1213-1232	
210	Adherence to statins and the risk of psoriasis: a population-based cohort study. <b>2015</b> , 173, 480-7	8
209	Lipid-lowering efficacy of atorvastatin. <b>2015</b> , CD008226	43
208	Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia. <b>2015</b> , 129, 71-8	5
207	A victory for statins or a defeat for diet policies? Cholesterol falls in Poland in the past decade: A modeling study. <b>2015</b> , 185, 313-9	5
206	Gender differences in lipid goal attainment among Chinese patients with coronary heart disease: insights from the DYSlipidemia International Study of China. <b>2015</b> , 17, B39-B46	
205	Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. <b>2016</b> , 9, 81-90	30
204	Efficacy of subgingivally delivered atorvastatin and simvastatin as an adjunct to scaling and root planing. <b>2015</b> , 30, 263-9	10
203	Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference. <b>2015</b> , 37, 2798-810	4
202	Disparities in lipid control and statin drug use among diabetics with noncoronary atherosclerotic vascular disease vs those with coronary artery disease. <b>2015</b> , 9, 241-6	4
201	Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. <b>2015</b> , 181, 417-24	18
200	Short-term effects of 2% atorvastatin dentifrice as an adjunct to periodontal therapy: a randomized double-masked clinical trial. <b>2015</b> , 86, 623-30	14
199	A novel therapeutic effect of statins on nephrogenic diabetes insipidus. <b>2015</b> , 19, 265-82	24
198	Stability and removal of atorvastatin, rosuvastatin and simvastatin from wastewater. <b>2015</b> , 36, 3232-42	14
197	The effect of statins on sympathetic activity: a meta-analysis. <b>2015</b> , 25, 125-31	22
196	Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. <b>2015</b> , 240, 415-23	90
195	Effect of Attending Practice Style on Generic Medication Prescribing by Residents in the Clinic Setting: An Observational Study. <b>2015</b> , 30, 1286-93	16
194	Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor. <b>2015</b> , 93, 316-25	22

193	Assessment of hepatic function, oxidant/antioxidant status, and histopathological changes in rats treated with atorvastatin: Effect of dose and acute intoxication with acetaminophen. <b>2015</b> , 34, 828-37	15
192	Chemometric technique for the optimization of chromatographic system: Simultaneous HPLC determination of Rosuvastatin, Telmisartan, Ezetimibe and Atorvastatin used in combined cardiovascular therapy. <b>2016</b> , 9, S1378-S1387	14
191	Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease. <b>2016</b> ,	0
190	Improvement of Glycemic Control in Insulin-Dependent Diabetics with Depression by Concomitant Treatment with Antidepressants. <b>2016</b> , 22, 2133-43	5
189	Management of intracerebral hemorrhage--use of statins. <i>Vascular Health and Risk Management</i> , <b>2016</b> , 12, 153-61	4-4 11
188	The Use of Statins in the Treatment and Prevention of Atrial Fibrillation. <b>2016</b> , 24, 224-9	3
187	Simultaneous Determination and Drug Dissolution Testing of Combined Amlodipine Tablet Formulations Using RP-LC. <b>2016</b> , 79, 1143-1151	6
186	1.2% Rosuvastatin Versus 1.2% Atorvastatin Gel Local Drug Delivery and Redelivery in Treatment of Intraony Defects in Chronic Periodontitis: A Randomized Placebo-Controlled Clinical Trial. <b>2016</b> , 87, 756-62	29
185	PCSK9 Inhibitors for Statin Intolerance?. <b>2016</b> , 315, 1571-2	13
184	Biochemistry of Statins. <b>2016</b> , 73, 127-68	16
183	Prospective analysis of association between statins and pancreatic cancer risk in the Women's Health Initiative. <b>2016</b> , 27, 415-23	13
182	Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia. <b>2016</b> , 253, 88-93	25
181	Laboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia: Pharmacogenetics of Statins. <b>2016</b> , 36, 473-91	4
180	Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia. <b>2016</b> , 252, 21-27	18
179	Simvastatin increases AQP2 urinary excretion in hypercholesterolemic patients: A pleiotropic effect of interest for patients with impaired AQP2 trafficking. <b>2016</b> , 99, 528-37	19
178	Platelet-Rich Fibrin Combined With 1.2% Atorvastatin for Treatment of Intraony Defects in Chronic Periodontitis: A Randomized Controlled Clinical Trial. <b>2016</b> , 87, 1039-46	22
177	Serum trans fatty acids, asymmetric dimethylarginine and risk of acute myocardial infarction and mortality in patients with suspected coronary heart disease: a prospective cohort study. <b>2016</b> , 15, 38	11
176	Rosuvastatin enhances anti-inflammatory and inhibits pro-inflammatory functions in cultured microglial cells. <b>2016</b> , 314, 47-63	31

175	Should Physicians be Encouraged to use Generic Names and to Prescribe Generic Drugs?. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1851-2	3	1
174	The effects of rosuvastatin on lipid-lowering, inflammatory, antioxidant and fibrinolytics blood biomarkers are influenced by Val16Ala superoxide dismutase manganese-dependent gene polymorphism. <b>2016</b> , 16, 501-506		30
173	Achieving cholesterol goals with low-cost 3-hydroxy-3-methylglutaryl coenzyme-A (HMG Co-A) reductase inhibitors. <b>2016</b> , 73, S63-8		1
172	Lipid Control and Beyond: Current and Future Indications for Statin Therapy in Stroke. <b>2016</b> , 18, 27		6
171	Management of residual risk after statin therapy. <b>2016</b> , 245, 161-70		47
170	Comparison of different statin therapy to change low-density lipoprotein cholesterol and high-density lipoprotein cholesterol level in Korean patients with and without diabetes. <b>2016</b> , 10, 528-537.e3		10
169	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. <b>2017</b> , 23, 1-87		535
168	Dose-Dependent Effect of Statin Pretreatment on Preventing the Periprocedural Complications of Carotid Artery Stenting. <b>2017</b> , 48, 1890-1894		23
167	Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. <b>2017</b> , 19, 62		3
166	The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. <b>2017</b> , 32, 949-965		39
165	High-Throughput Assay for Enantiomeric Excess Determination in 1,2- and 1,3-Diols and Direct Asymmetric Reaction Screening. <b>2017</b> , 23, 10222-10229		25
164	Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view. <b>2017</b> , 134, 159-184		273
163	Implications of cerebrovascular ATP-binding cassette transporter G1 (ABCG1) and apolipoprotein M in cholesterol transport at the blood-brain barrier. <b>2017</b> , 1862, 573-588		24
162	Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome. <b>2017</b> , 70, 1732-1740		79
161	The effect of local and systemic statin use as an adjunct to non-surgical and surgical periodontal therapy-A systematic review and meta-analysis. <b>2017</b> , 67, 18-28		27
160	Optimal Medical Management Reduces Risk of Disease Progression and Ischemic Events in Asymptomatic Carotid Stenosis Patients: A Long-Term Follow-Up Study. <b>2017</b> , 44, 150-159		12
159	Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease. <b>2017</b> , 187, 2895-2911		18
158	The balance between induction and inhibition of mevalonate pathway regulates cancer suppression by statins: A review of molecular mechanisms. <b>2017</b> , 273, 273-285		28

157	Simultaneous separation of antihyperlipidemic drugs by green ultrahigh-performance liquid chromatography-diode array detector method: Improving the health of liquid chromatography. <b>2017</b> , 25, 430-437	8
156	Efficacy and tolerability of two different formulations of atorvastatin in Korean patients with hypercholesterolemia: a multicenter, prospective, randomized clinical trial. <b>2017</b> , 11, 2277-2285	2
155	Comparative evaluation of efficacy of subgingivally delivered 1.2% Atorvastatin and 1.2% Simvastatin in the treatment of intrabony defects in chronic periodontitis: a randomized controlled trial. <b>2017</b> , 11, 18-25	13
154	Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians. <b>2017</b> , 15, e43319	25
153	Fluvastatin for lowering lipids. <b>2018</b> , 3, CD012282	16
152	Statin use and risk of skin cancer. <b>2018</b> , 78, 682-693	10
151	Spatial structure of atorvastatin and its complex with model membrane in solution studied by NMR and theoretical calculations. <b>2018</b> , 1167, 69-77	9
150	Biocatalysis for synthesis of pharmaceuticals. <b>2018</b> , 26, 1252-1274	93
149	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. <b>2018</b> , 12, 130-136	27
148	Statins in nonsurgical and surgical periodontal therapy. A systematic review and meta-analysis of preclinical in vivo trials. <b>2018</b> , 53, 267-287	24
147	Effects of statins on the chemoresistance-The antagonistic drug-drug interactions versus the anti-cancer effects. <b>2018</b> , 108, 1856-1865	17
146	Simvastatin Suppresses Interleukin IIRelease in Human Peripheral Blood Mononuclear Cells Stimulated With Cholesterol Crystals. <b>2018</b> , 23, 509-517	13
145	Indoles: As Multitarget Directed Ligands in Medicinal Chemistry. <b>2018</b> , 285-321	6
144	Ischemic Coronary Artery Disease. <b>2018</b> , 317-322	
143	Hypercholesterolaemia - practical information for non-specialists. <b>2018</b> , 14, 1-21	30
142	In vivo evaluation of hypolipidemic and antioxidative effect of 'Ajwa' (Phoenix dactylifera L.) date seed-extract in high-fat diet-induced hyperlipidemic rat model. <b>2018</b> , 107, 675-680	24
141	The effectiveness of lotus stamen tea on lowering blood lipid level in hyperlipidemic subjects. <b>2018</b> , ,	1
140	A new rational approach to reach LDL-cholesterol concentration objectives after an acute coronary syndrome. <b>2019</b> , 31, 93-100	0

139	Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. <b>2019</b> , 47, 751-767	20
138	Characterization of solid dispersions of a powerful statin using thermoanalytical techniques. <b>2019</b> , 138, 3701-3714	2
137	Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease. <b>2019</b> , 1, 100002	2
136	Direct electrosynthesis for N-alkyl-C3-halo-indoles using alkyl halide as both alkylating and halogenating building blocks. <b>2019</b> , 21, 2732-2738	26
135	What is new in lipid-lowering therapies in diabetes?. <b>2019</b> , 49, 1472-1480	4
134	Acceptability of Localized Cancer Risk Reduction Interventions Among Individuals at Average or High Risk for Cancer. <b>2019</b> , 12, 271-282	5
133	Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. <b>2019</b> , 20, 917-928	6
132	Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. <b>2019</b> , 24, 315-322	11
131	Latest Updates on Lipid Management. <b>2019</b> , 26, 85-100	3
130	A new rational approach to reach LDL-cholesterol concentration objectives after an acute coronary syndrome. <b>2019</b> , 31, 93-100	4
129	Association between osteoporosis and statins therapy: the story continues. <b>2021</b> , 80, e204	2
128	State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications. <b>2019</b> , 33, 625-639	13
127	The effects of statins with a high hepatoselectivity rank on the extra-hepatic tissues; New functions for statins. <b>2020</b> , 152, 104621	3
126	Genetic disorders of lipoprotein metabolism. <b>2020</b> , 245-265	
125	Antihyperlipidemic and hepatic antioxidant effects of Leek leaf methanol extract in high fat diet-fed rats. <b>2020</b> , 13, 373-385	2
124	Bavachinin inhibits cholesterol synthesis enzyme FDFT1 expression via AKT/mTOR/SREBP-2 pathway. <b>2020</b> , 88, 106865	6
123	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. <b>2020</b> , 26, 1196-1224	27
122	Mutation spectrum and polygenic score in German patients with familial hypercholesterolemia. <b>2020</b> , 98, 457-467	5

121	Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia. <b>2020</b> , 9, 162-171	3
120	Lovastatin protects against cisplatin-induced hearing loss in mice. <b>2020</b> , 389, 107905	18
119	An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. <b>2020</b> , 21, 531-539	8
118	Effect of statins on orthodontic tooth movement: A systematic review of animal and clinical studies. <b>2020</b> , 111, 104665	2
117	The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer. <b>2020</b> , 80, 1293-1303	22
116	Pharmacists' considerations on non-medical switching at the hospital: a systematic review of the economic outcomes of cost-saving therapeutic drug classes. <b>2021</b> , 28, e2-e7	0
115	PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance. <b>2021</b> , 35, 61-68	3
114	Base-mediated sequential one-pot approach for the synthesis of 2,3-disubstituted indoles from 2-(tosylamino)aryl-substituted para-quinone methides. <b>2021</b> , 82, 131950	4
113	Impact of statin pretreatment on the complications of carotid stenting in asymptomatic patients: observational study. <b>2021</b> , 21, 75	
112	LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry. <b>2021</b> , 1	
111	Atherosclerosis: Cholesterol Management. 1-36	
110	Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia. <b>2021</b> , 31, 1594-1603	1
109	When Are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials?. <b>2021</b> ,	1
108	Statin-boosted cellular uptake and endosomal escape of penetratin due to reduced membrane dipole potential. <b>2021</b> , 178, 3667-3681	4
107	Prevalence of SLCO1B1 single nucleotide variations and their association with hypercholesterolaemia in hypercholesterolemic patients in Gauteng, South Africa. <b>2021</b> , 51, 949-959	
106	Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs. <b>2021</b> , 161, 105776	2
105	Role of Cod Liver Oil in Reducing Elevated Lipid Parameters. <b>2021</b> , 13, e15556	1
104	Association of Pre-Admission Statin Use With Reduced In-Hospital Mortality in COVID-19. <b>2021</b> , 361, 725-730	7

103	Inflammation Markers in Adipose Tissue and Cardiovascular Risk Reduction by Pomegranate Juice in Obesity Induced by a Hypercaloric Diet in Wistar Rats. <b>2021</b> , 13,	2
102	Genome-Wide Association Meta-Analysis Using a Recessive Model Illuminates Genetic Architecture of Type 2 Diabetes.	
101	Atherosclerotic Cardiovascular Disease Risk and Statin Prescription Status in Korean Adult Patients. <b>2021</b> , 31, 198-204	0
100	Atorvastatin is associated with reduced cisplatin-induced hearing loss. <b>2021</b> , 131,	13
99	Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. <b>2000</b> , 41, 1136-1144	49
98	Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. <b>1999</b> , 40, 1078-1089	47
97	Lipid-lowering drugs: who gets what?. <b>1998</b> , 9, 289-94	7
96	Primary and secondary prevention of coronary artery disease: a follow-up on clinical controlled trials. <b>1998</b> , 9, 557-64	5
95	Nutritional and medical therapy for dyslipidemia in patients with cardiovascular disease. <b>2001</b> , 12, 40-52	1
94	An Effector Index to Predict Causal Genes at GWAS Loci.	3
93	Statin-boosted cellular uptake of penetratin due to reduced membrane dipole potential.	1
92	Effectiveness of lipid lowering drugs in general practice: study had two major flaws. <b>2003</b> , 327, 51; author reply 51	1
91	More on switching statins: comments from Pfizer. <b>2006</b> , 333, 655; author reply 655-6	0
90	A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin. <b>2002</b> , 42, 963-970	11
89	Atherosclerosis. <b>2002</b> , 413-457	1
88	Cholesterol Lowering Effects of Low-dose Statins in Korean Patients. <b>2014</b> , 3, 21	21
87	Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an observational study from the Swedish National Diabetes Register. <b>2011</b> , 6, e18744	23
86	Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory. <b>2013</b> , 8, e75467	38



85	Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration. <b>2013</b> , 8, e83759	52
84	Quantifying the contribution of statins to the decline in population mean cholesterol by socioeconomic group in England 1991 - 2012: a modelling study. <b>2015</b> , 10, e0123112	8
83	Circulating B-vitamins and smoking habits are associated with serum polyunsaturated Fatty acids in patients with suspected coronary heart disease: a cross-sectional study. <b>2015</b> , 10, e0129049	5
82	Camphene, a Plant Derived Monoterpene, Exerts Its Hypolipidemic Action by Affecting SREBP-1 and MTP Expression. <b>2016</b> , 11, e0147117	12
81	High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort. <b>2016</b> , 11, e0151587	39
80	Lovastatin, not Simvastatin, Corrects Core Phenotypes in the Fragile X Mouse Model. <b>2019</b> , 6,	14
79	Atorvastatin: evidence base 15 years later. <b>2011</b> , 10, 103-112	4
78	Possible association of ABCB1:c.3435T>C polymorphism with high-density-lipoprotein-cholesterol response to statin treatment--a pilot study. <b>2014</b> , 14, 144-9	11
77	Efficacy and safety of atorvastatin in South Asian patients with dyslipidemia: an open label noncomparative pilot study. <i>Vascular Health and Risk Management</i> , <b>2005</b> , 1, 351-6	4.4 9
76	Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter?. <i>Vascular Health and Risk Management</i> , <b>2006</b> , 2, 441-6	4.4 2
75	Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders. <b>2016</b> , 14, 280-7	8
74	Mevalonate pathway as a novel target for the treatment of metastatic gastric cancer. <b>2020</b> , 20, 320	4
73	Flexible initial dosing of atorvastatin based upon initial low-density lipoprotein cholesterol levels in type 2 diabetic patients. <b>2008</b> , 23, 22-9	9
72	Comparative Drug Evaluation of Atorvastatin versus Rosuvastatin in Pharmacotherapy of Korean Patients with Dyslipidemia. <b>2008</b> , 16, 54-60	2
71	Lipid-lowering effect of hydroalcoholic extracts of <i>Gynura procumbens</i> in Chemical- and High-fat diet-induced hyperlipidemic rats. <b>2018</b> , 14, 184	4
70	Long-term outcome after statin treatment in routine clinical practice: results from a prospective PCI cohort study. <b>2012</b> , 7, 1420-7	5
69	Assessing the adherence to and the therapeutic effectiveness of hypolipidemic agents in a population of patients in Brazil: a retrospective cohort study. <b>2014</b> , 12, 378	7
68	Antihyperlipidemic Activities of a Chemically Engineered Sulfated Mushroom $\beta$ glucan on High Fat Dietary-induced Hyperlipidemia in Sprague-Dawley Rats. <b>2014</b> , 24, 1209-1216	3

- 67 Pravastatin sodium, an inhibitor of HMG-CoA reductase, decreases HDL cholesterol by transfer of cholesteryl ester from HDL to VLDL in Japanese white rabbits. **2004**, 11, 22-8 5
- 66 The multifaceted biology of PCSK9. **2021**, 9
- 65 Lipidsenker und Reokklusionsprophylaxe. **2000**, 69-88
- 64 Stoffwechsel und endokrine Erkrankungen. **2000**, 255-310
- 63 Lipid-Lowering Drugs. **2000**, 155-177
- 62 Generika und Analogpräparate. **2001**, 687-713
- 61 Hyperlipidemias and Nutrient-Gene Interactions. **2001**,
- 60 Acquired Myopathies. **2002**, 1371-1432 1
- 59 References. **2002**, 106, 3373-3421 1
- 58 Lipid-Lowering Drugs. **2003**, 165-191
- 57 Effectiveness of lipid lowering drugs in general practice: article illustrates major problem. **2003**, 327, 50-1; author reply 51
- 56 Vliyanie gipolipidemicheskoy terapii na insulinorezistentnost' u patsientov s metabolicheskim sindromom. **2004**, 1, 16-18
- 55 Pharmacological Treatments of Lipid Abnormalities. **2005**, 183-212
- 54 Effect of Changing from Pravastatin to Atorvastatin on Serum Cholesterol Levels. **2006**, 32, 553-557
- 53 Cardiac Rehabilitation: Statins and the Rationale for Implementation of Lipid-Lowering Therapy. **2007**, 141-156
- 52 Special Considerations in Research. **2007**, 275-350
- 51 Lowering Low-Density Lipoprotein Cholesterol Levels to Reduce Atherosclerotic Coronary Heart Disease Risk. **2007**, 221-240
- 50 Management of Diabetic Dyslipidaemia. **2007**, 173-186

- 49 Hyperlipidemias. **2007**, 715-726
- 48 Bioequivalence of Atorva Tablet to Lipitor Tablet (Atorvastatin 20 mg). **2008**, 38, 135-142
- 47 The efficacy and safety of combination therapy with atorvastatin and tacrolimus in heart transplant recipients. **2008**, 50, 368-372
- 46 Treatment Guidelines Overview. **2009**, 202-216
- 45 Cost-effective management of dyslipidaemia.. **2009**, 2009,
- 44 Genotype-Guided Statin Therapy. **2011**, 155-174
- 43 Drug Therapy and Follow-Up. **2011**, 563-631
- 42 Nutritional Approaches for Cardiovascular Disease Prevention. **2011**, 253-271
- 41 How are statins used in the Czech Republic? STEP survey - results. **2011**, 53, 527-534 3
- 40 Metabolic Disorders. **2012**, 727-766
- 39 ANTIATHEROGENIC AND PLEIOTROPIC ACTIVITY OF VARIOUS DOSES OF ATORVASTATIN IN PATIENTS WITH ISCHEMIC STROKE. **2013**, 12, 41-50
- 38 Use of Cholesterol-Lowering Medications of Patients with Myocardial Infarction from 2007-2015 in Cardiology Clinic to Mother Teresa University Hospital in Albania. **2016**, 07, 236-245
- 37 Efficacy and safety of Zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease. **2018**, 9, 9489-9497 1
- 36 Comparative assessment of different marketed brands of atorvastatin tablets in Asir region, Saudi Arabia. **2018**, 2,
- 35 Hemodynamic impact of positive end expiratory pressure in right cardiac performance. **2019**, 12, 131-133 0
- 34 The impact of adjuvant atorvastatin therapy on community-acquired pneumonia outcome: a prospective study of clinical and inflammatory responses in relation to mortality reduction. **2019**, 13, 249-257
- 33 Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. **2019**, 66, 54-63 1
- 32 Familial hypercholesterolemia: clinical pearls. **2019**, 12, 127-129

31	Euvascor - early intervention of hypertension and dyslipidaemia (dual combination of atorvastatin and perindopril). <i>Vnitřni Lekarstvi</i> , <b>2020</b> , 66, 190-195	0.3	
30	Comparative analysis of the use of lipid modifying agents in the Republic of Serbia and Nordic countries in the period 2015-2017. <i>Hospital Pharmacology</i> , <b>2020</b> , 7, 966-975	0.2	
29	Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2020</b> , 182, 113128	3.5	
28	Comparative efficacy and safety of atorvastatin, simvastatin and lovastatin in the management of dyslipidemic Type 2 diabetic patients. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2006</b> , 3, 759-764		1
27	Entropy-probabilistic modeling as a tool for forming key competencies of a doctor. <i>Journal of Physics: Conference Series</i> , <b>2020</b> , 1691, 012162	0.3	
26	Did the major clinical trials of statins affect prescribing behaviour?. <i>Cmaj</i> , <b>2001</b> , 164, 1695-6	3.5	10
25	Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies. <i>Clinical Biochemist Reviews</i> , <b>2004</b> , 25, 31-48	7.3	7
24	New Zealand cardiovascular guidelines: best practice evidence-based guideline: the assessment and management of cardiovascular risk December 2003. <i>Clinical Biochemist Reviews</i> , <b>2007</b> , 28, 19-29	7.3	7
23	Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. <i>Vascular Health and Risk Management</i> , <b>2007</b> , 3, 733-42	4.4	10
22	Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. <i>Experimental and Clinical Cardiology</i> , <b>2007</b> , 12, 91-6		3
21	From evidence to practice: consensus in cardiovascular risk assessment and diabetes. <i>Clinical Biochemist Reviews</i> , <b>2009</b> , 30, 179-86	7.3	2
20	Statins as first-line therapy for acute coronary syndrome?. <i>Experimental and Clinical Cardiology</i> , <b>2012</b> , 17, 227-36		9
19	Performance evaluation of a novel potentiometric membrane sensor for determination of atorvastatin in pharmaceutical preparations. <i>Iranian Journal of Pharmaceutical Research</i> , <b>2013</b> , 12, 645-57 <sup>1.1</sup>		3
18	The effects of different doses of atorvastatin on serum lipid profile, glycemic control, and liver enzymes in patients with ischemic cerebrovascular accident. <i>ARYA Atherosclerosis</i> , <b>2014</b> , 10, 298-304	0.7	5
17	Factors Associated with Lipid Goal Attainment among Patients with Deployed Drug Eluting Stent. <i>Acta Cardiologica Sinica</i> , <b>2014</b> , 30, 325-32	1.1	1
16	Cardiovascular prevention: early and consistent prevention versus late intervention, complex approach to the treatment of modifiable risk factors: hypertension and dyslipidemia. <i>Vnitřni Lekarstvi</i> , <b>2021</b> , 67, 412-418	0.3	
15	Recessive Genome-wide Meta-analysis Illuminates Genetic Architecture of Type 2 Diabetes. <i>Diabetes</i> , <b>2021</b> ,	0.9	0
14	Prevalence of statin intolerance: a meta-analysis.. <i>European Heart Journal</i> , <b>2022</b> ,	9.5	8

13	Continuous Wavelet Transform for Simultaneous Determination of Atorvastatin and Rosuvastatin in Combined Pharmaceutical Formulations. <i>Journal of Applied Spectroscopy</i> , <b>2022</b> , 88, 1195-1201	0.7	
12	An effector index to predict target genes at GWAS loci.. <i>Human Genetics</i> , <b>2022</b> , 1	6.3	○
11	An experimental medicine study of the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation in healthy volunteers.. <i>Psychopharmacology</i> , <b>2022</b> ,	4.7	○
10	Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?. <b>2022</b> , 23, 9326		○
9	A step further in uncontrolled hyperlipidemia. <b>2022</b> , 1, 49-59		○
8	Are Current Guidelines Perpetuating Weight Stigma? A Weight-Skeptical Approach to the Care of Patients with Obesity.		○
7	Associated factors for discontinuation of statin use one year after discharge in patients with acute coronary syndrome in China. <b>2022</b> , 12, e056236		○
6	Contemporary National Patterns of Eligibility and Use of Novel Lipid-Lowering Therapies in the United States. <b>2022</b> , 11,		○
5	Rosuvastatin-Induced Dizziness and Pruritus: A Case Report and Summary of Statin-Associated Dizziness and Pruritus. <b>2022</b> ,		○
4	Statin-Induced Geranylgeranyl Pyrophosphate Depletion Promotes Ferroptosis-Related Senescence in Adipose Tissue. <b>2022</b> , 14, 4365		○
3	A cross-country utilization patterns comparison of high expenditure therapeutic groups between Portugal and six European countries: the two sides of the Portuguese coin. 1-9		○
2	Simvastatin therapy in different subtypes of hypercholesterolemia ▯ physiologically based modelling approach.		○
1	Lipid-lowering Efficacy and Safety of High Doses of Atorvastatin and Rosuvastatin. <b>2023</b> , 63, 59-67		○